Treatment

Implications of heterogeneity in Alzheimer’s disease

Limitations in understanding Alzheimer’s disease for gene editing

Mechanisms influencing mitochondrial dysfunction in Alzheimer’s disease

Immunotherapy in treating Alzheimer’s disease

Inhibition of CXCR4/CXCL12 signaling: a translational perspective for Alzheimer’s disease treatment

Increasing the expression of Mer receptors in microglia: a potential therapy for Alzheimer’s disease

Targeting the AMPK cascade to rescue mitochondrial dysfunctions in Alzheimer’s disease

Antibody-based therapy in Alzheimer’s disease: future outlook

Comparing binding characteristics to Aβ of lecanemab, aducanumab & gantenerumab

Advances in Alzheimer’s disease biomarkers & therapies

Lecanemab path to approval

Transcription-based drug repurposing in Alzheimer’s disease with psychosis

Potential of targeting the gut microbiome to treat Alzheimer’s disease

Epigenetics in prion diseases

Research into the effect of the gut microbiome on Alzheimer’s disease at ARUK 2022

Impact of blood-based biomarkers on Alzheimer’s disease treatments